Inhibrx Biosciences, Inc. · NASDAQ:INBX
Inhibrx Biosciences — Investor Presentation (January 2022)
41 slides from Inhibrx Biosciences's investor presentation, January 2022
Slide 1: Innovation Driven, Outcomes Focused
Innovation Driven Outcomes Focused January 2022
Slide 2: Presentation disclaimer
Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can could differ materially from the plans, intentions and expectations disclosed in the identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” forward-looking statements t
Slide 3: Four differentiated clinical programs
Four differentiated clinical programs Rare diseases Oncology Cell death pathway Immuno-oncology INBRX-101 INBRX-109 INBRX-106 INBRX-105 AAT-Fc fusion protein Tetravalent DR5 agonist Hexavalent OX40 agonist PD-L1 x 4-1BB tetravalent + Potential for first meaningful + Single agent activity + Durable p
Slide 4: Why invest in Inhibrx?
Why invest in Inhibrx? KEY FINANCIAL HIGHLIGHTS* $141.1M Cash Four differentiated clinical Potential to reach programs with value-creating financial sustainability readouts in 2022/2023 with minimal dilution $25M Average per Qtr burn rate 38.9M Common stock outstanding Backed by solid institutional
Slide 5: Inhibrx at a glance
Inhibrx at a glance PARTNERSHIPS WITH INDUSTRY LEADERS + Experienced leadership team All platforms and programs + Proven innovation and execution developed in-house with strong patent protection + Ability to precision engineer to specific target biology + Smaller than conventional antibodies + Antib
Slide 6: INBRX-106
INBRX-106 Hexavalent OX40 Agonist
Slide 7: Hexavalent OX40 agonist
Hexavalent OX40 agonist OX40: sdAb OX40: sdAb OX40 is a co-stimulatory receptor on activated T-cells: OX40: sdAb OX40: sdAb + Provides co-stimulation to activated T-cells + Reverses regulatory T-cell induced OX40: sdAb OX40: sdAb immune suppression + Enhances T-cell functionality + Additional benefi
Slide 8: INBRX-106 is a best-in-class OX40 agonist
INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) Bivalent anti- INBRX-106 OX40 Hexavalent MOXR-0916 Discontinued GSK-3174998 Discontinued Ox40 OX40 BMS-986178 Ph 1 (2016) INCAGN-1949 Bi- IgG1 Y Ph 1 (2016) ABBV-368 Ph 1 (H
Slide 9: INBRX-106 Phase 1 in combination with Keytruda
INBRX-106 Phase 1 in combination with Keytruda™ PART 3 PART 4 Dose Dose escalation expansion Complete Initiated N=21 N=80 No pre-screening, all-comers CPI refractory CPI naive PD-L1+ cutaneous N=20 PD-L1+ NSCLC N=10 melanoma N=20 PD-L1+ basket N=10 PD-L1+ uveal melanoma N=10 PD-L1+ head & neck + Exa
Slide 10: INBRX-106 Phase 1 preliminary single agent activity
INBRX-106 Phase 1 preliminary single agent activity PART 1 PART 2 Dose escalation Dose expansion Complete Ongoing N=20 N=24 Patients were all-comers 0.03 mg/kg in two different dosing schedules in patients with tumor types responsive to CPIs + 4/10 response evaluable NSCLC & melanoma patients with d
Slide 11: Market opportunity
Market opportunity PD-1/PD-L1 WW Revenue PD-1/PD-L1 WW Revenue by Indication (in $ billions) (in $ billions) $70 $63.5 NSCLC 2020 2020 Projected 2026 $60 Melanoma Renal cell $50 carcinoma Bladder cancer $40 Head & neck cancers $30 $27.1 $28.2 Gastrointestinal adenocarcinoma $20 SCLC $14.4 $14.2 $10.
Slide 12: INBRX-101
AAT INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein Fc
Slide 13: Alpha-1 antitrypsin deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) AAT Serum levels in patients receiving weekly pdAAT 60 Disease overview + AATD is an inherited orphan respiratory disease characterized by deficient levels Mean Serum AAT level (μM) of alpha-1 antitrypsin (AAT) causing loss 40 Normal AAT of lung function and dec
Slide 14: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101
Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential advantages of INBRX-101 Potential to extend Goal is to maintain patients Recombinant manufacturing the dosing interval in the normal serum range provides unlimited supply from weekly to monthly of AAT and to normalize and
Slide 15: AATD therapeutic landscape
AATD therapeutic landscape 100% Applicable to all patients 15% Applicable to ~15% of patients with liver issues THERAPIES THERAPIES Aralast ARO-AAT Glassia DCR-A1AT Plasma-Derived AAT Prolastin-C Zemaira Inhaled AAT Oral Neutrophil Alvelestat Elastase Inhibitor Small Molecule ZF874 Corrector 15
Slide 16: INBRX-101 initial results from Phase 1, Part 1
INBRX-101 - Initial results from Phase 1, Part 1 PART 1 Key functional AAT levels by dose Single ascending 60 dose escalation (SAD) Complete Functional AAT levels (μM) N=24 40 Baseline AAT Max AAT N=6 10 mg/kg Day 21 AAT N=6 40 mg/kg 20 N=6 80 mg/kg N=6 120 mg/kg 0 10 40 80 120 INBRX-101 single asce
Slide 17: INBRX-101 initial results from Phase 1, Part 2
INBRX-101 - Initial results from Phase 1, Part 2 - 40 mg/kg PART 2 INBRX-101 Initial Results - 40 mg/kg (Q3W) Multiple ascending 40 dose escalation (MAD) Functional AAT levels (μM) 30 N=18 N=6 40 mg/kg 20 Complete N=6 80 mg/kg* 10 N=6 120 mg/kg* Ongoing 0 0 21 42 63 * bronchoalveolar lavage Time (da
Slide 18: INBRX-109
INBRX-109 Tetravalent DR5 Agonist
Slide 19: Tetravalent DR5 agonist
Tetravalent DR5 agonist DR5: sdAb DR5: sdAb + Death receptor 5 (DR5) is a receptor DR5: sdAb DR5: sdAb for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells Fc: effector function disabled 105 kDa 19
Slide 20: INBRX-109 is a best-in-class DR5 agonist
INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) INBRX-109 Tetravalent 105 TAS-2661 Tetravalent 60 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 GEN10291,2 Dodecavalent 150 ka (2x mAbs) IGM-8444 Decavalent3 ~950 Dulanermin (recombinant TRAIL) Trivalent 150 Tigatuzumab LBY-
Slide 21: Fast to market opportunity
Fast to market opportunity Chondrosarcoma PFS from placebo-controlled Incidence rate chondrosarcoma studies of ~1 in 200,000 persons per year Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Placebo arm Median PFS 2.9 months ~1,400 cases per Source~ CTOS 2013 Wagner et al. year
Slide 22: Preliminary Phase 1 data in conventional chondrosarcoma
Preliminary Phase 1 data in unresectable or metastatic conventional chondrosarcoma Best Response 3mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD (+7%) PD (+31
Slide 23: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma
INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization Conventional chondrosarcoma, Grades 1, INBRX-109 Placebo 2 and 3, unresectable or metastatic N=134* N=67 * Stratification 3 mg/kg every Until PD or toxicity by line of therapy, Grade and IDH1/2 three weeks with cros
Slide 24: Phase 1 single agent data in malignant pleural mesothelioma
Phase 1 single agent data in malignant pleural mesothelioma, epithelioid subtype PARTs 1 & 2 Best Response 3mo 6mo 9mo SD (-24%) * SD (-17%) PART 3 SD (-12%) Combination PR (-100%) study SD (-22%) SD (-20%) N=10 Mesothelioma with SD (-12%) Cisplatin or SD (-5%) Carboplatin SD (-2%) N=10 Mesothelioma
Slide 25: INBRX-109 on the horizon
INBRX-109 on the horizon POTENTIAL FUTURE PART 3 OPPORTUNITIES Combination studies Solid tumors + IAP antagonists Pancreatic adenocarcinoma N=20 Hematologic tumors 2nd line with mFOLFIRI Ongoing + Bcl-2 inhibitors Ewing sarcoma with NSCLC N=20 Irinotecan + Temozolomide + various combo agents Ongoing
Slide 26: INBRX-105
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 27: PD-L1 x 4-1BB multispecific
PD-L1 x 4-1BB multispecific PD-L1: sdAb PD-L1: sdAb + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune 4-1BB: sdAb 4-1BB: sdAb cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive
Slide 28: INBRX-105 is a potential best-in-class 4-1BB agonist
INBRX-105 is a potential best-in-class 4-1BB agonist PD-L1 x 4-1BB Bispecifics CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/
Slide 29: INBRX-105 Phase 1 trial design
INBRX-105 Phase 1 trial design PART 1 PART 2 PART 3 PART 4 Single agent Complete Single agent Ongoing Dose escalation Initiated Dose expansion Planned dose escalation dose expansion with Keytruda™ with Keytruda™ N=32 N=32 N=15+ N=80 Single agent: PD-L1+ basket No pre-screening, all-comers N=20 PD-L1
Slide 30: Molecular Targeted Cytokine (MTC) Platform
Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform
Slide 31: Affinity differential enables directed IL-2 expansion
Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity sdAb sdAb High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors Fc – effector function + Inh
Slide 32: INBRX-121
INBRX-121 NKp46 Targeted Detuned IL-2
Slide 33: INBRX-121 expands the NK cell population and enhances cytotoxicity
INBRX-121 expands the NK cell population and enhances cytotoxicity NKp46 sdAb NKp46 sdAb + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells Fc – effector function + Proprietary IL2-X engineering disabled ensures specific modulation of NK Cells without impacting
Slide 34: INBRX-121 is poised to bring NK cells to the forefront of immunotherapy
INBRX-121 is poised to bring NK cells to the forefront of immunotherapy Improved NK Activity Safety with durability Multiple paths forward INBRX-121 NK NK Single agent NK NK Activated NK cells NK NK CYTOKINES exhibit immediate NK NK NK cytotoxicity NK INBRX-121 Combination therapy ⁺ Expands NK cell
Slide 35: Expands mouse NK cells and enhances their cytotoxic potential
Expands mouse NK cells and enhances their cytotoxic potential NK cell expansion NK cell activation NK cell cytolytic activity 25 5,000 20,000 Max. fold-change (relative to vehicle) 20 4,000 15,000 Granzyme B levels 15 3,000 KLRG1 levels 10,000 10 2,000 5,000 5 1,000 0 0 0 NK cells CD8 T cells Tregs
Slide 36: Synergizes with approved therapeutic antibodies
Synergizes with approved therapeutic antibodies Raji tumor growth 2,000 Vehicle 1,500 INBRX-121 Tumor Volume (mm3) 1,000 Rituxan INBRX-121 synergizes with Rituxan® INBRX-121 + Rituxan in a subcutaneous 500 Raji tumor model resulting in complete 0 tumor regression 0 7 14 21 28 35 42 Dosing Time (days
Slide 37: INBRX-121 safely expands NK cells in non-human primates
INBRX-121 safely expands NK cells in non-human primates NK cell expansion in blood after NK Expands NK cells a single dose of INBRX-121 at 1 mg/kg: NK in a dose-dependent NK NK manner (up to 12-fold) Frequency of lymphocytes NK NK NK NK that persists for more than Pre-dose Day 10 NK 21 days and can
Slide 38: Expands NK cells from lymphoma patients
Expands NK cells from Lymphoma patients IL-2 signaling in patient NK cells Patient NK cell proliferation 60 60 % pSTAT5 positive 40 40 % Ki67 positive 20 20 0 0 INBRX-121 - + - + - + - + INBRX-121 - + - + - + - + DLBCL MCL FL Healthy DLBCL MCL FL Healthy Donor Donor NK cells from Lymphoma patients e
Slide 39: Expands the number of NK cells while enhancing cytotoxic capacities
Expands the number of NK cells while enhancing their individual cytotoxic capacities 120 100 80 %Target celldeath Anti-hCD20-hlgG1 only INBRX-121 increases NK 60 Anti-hCD20-hlgG1 + cell-mediated killing of 40 INBRX-121 Raji cells in the presence of a Rituximab sequence 20 analog (Anti-hCD20- hIgG1).
Slide 40: Near term expected clinical milestones
Near term expected clinical milestones INBRX-106 (OX40) / Keytruda INBRX-105 initial dose expansion INBRX-105 cohort data (PD-L1 x 41BB) (PD-L1 x 41BB) Keytruda dose Keytruda dose escalation data INBRX-101 expansion cohort data (AAT) Potential start to registration study 1H 2022 2H 2022 1H 2023 INBR
Slide 41: 11025 N. Torrey Pines Rd, La Jolla, CA
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com